First-in-class ACP3 high-affinity ligands isolated from DNA-encoded chemical libraries for the delivery of radionuclides against prostate cancer
DOI:
文献链接:
其他信息:
S Cazzamalli, T Georgiev, F Migliorini, A Ciamarone…
2024
jnm.snmjournals.org
241120 Introduction: Lutetium Vipivotide Tetraxetan (Pluvicto TM, a Novartis product), a PSMA-targeted Radio Ligand Therapeutic (RLT), has revolutionized the treatment of metastatic castration-resistant prostate cancer. Despite the clinical benefit observed in large pivotal trials, virtually all patients treated with the drug eventually relapse (VISION trial). Moreover, the product shows an on-target off tumor uptake in healthy tissues, such as salivary glands and kidneys, which is responsible for certain toxicities observed in the clinic …

